Johnson & Johnson Return on Tangible Equity 2010-2024 | JNJ
Current and historical return on tangible equity values for Johnson & Johnson (JNJ) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Johnson & Johnson Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-09-30 |
$14.68B |
$-14.13B |
-199.72% |
| 2024-06-30 |
$38.02B |
$-12.44B |
-1000.80% |
| 2024-03-31 |
$38.48B |
$-0.88B |
-853.36% |
| 2023-12-31 |
$35.15B |
$-1.96B |
-357.73% |
| 2023-09-30 |
$34.62B |
$0.08B |
-394.80% |
| 2023-06-30 |
$13.05B |
$-15.28B |
-152.31% |
| 2023-03-31 |
$12.72B |
$-22.15B |
-264.77% |
| 2022-12-31 |
$17.94B |
$2.27B |
-4184.49% |
| 2022-09-30 |
$19.16B |
$0.88B |
-660.70% |
| 2022-06-30 |
$18.37B |
$-0.22B |
-287.52% |
| 2022-03-31 |
$19.83B |
$-4.65B |
-189.68% |
| 2021-12-31 |
$20.88B |
$-7.62B |
-143.65% |
| 2021-09-30 |
$17.88B |
$-13.07B |
-92.84% |
| 2021-06-30 |
$17.77B |
$-16.48B |
-87.95% |
| 2021-03-31 |
$15.12B |
$-20.96B |
-73.16% |
| 2020-12-31 |
$14.71B |
$-26.52B |
-72.49% |
| 2020-09-30 |
$16.99B |
$-16.84B |
-88.83% |
| 2020-06-30 |
$15.19B |
$-18.33B |
-73.55% |
| 2020-03-31 |
$17.17B |
$-19.52B |
-79.42% |
| 2019-12-31 |
$15.12B |
$-21.81B |
-70.04% |
| 2019-09-30 |
$14.15B |
$-22.93B |
-68.33% |
| 2019-06-30 |
$16.33B |
$-22.21B |
-87.54% |
| 2019-03-31 |
$14.68B |
$-19.39B |
-83.96% |
| 2018-12-31 |
$15.30B |
$-18.31B |
-86.43% |
| 2018-09-30 |
$1.54B |
$-14.71B |
-7.96% |
| 2018-06-30 |
$1.37B |
$-17.51B |
-7.35% |
| 2018-03-31 |
$1.25B |
$-20.26B |
-6.98% |
| 2017-12-31 |
$1.30B |
$-24.97B |
-14.82% |
| 2017-09-30 |
$15.83B |
$-11.90B |
596.35% |
| 2017-06-30 |
$16.34B |
$-14.25B |
146.93% |
| 2017-03-31 |
$16.51B |
$16.03B |
79.16% |
| 2016-12-31 |
$16.54B |
$20.74B |
71.66% |
| 2016-09-30 |
$15.94B |
$21.96B |
66.88% |
| 2016-06-30 |
$15.03B |
$24.68B |
61.54% |
| 2016-03-31 |
$15.55B |
$24.96B |
65.03% |
| 2015-12-31 |
$15.41B |
$23.76B |
68.35% |
| 2015-09-30 |
$14.72B |
$24.29B |
67.57% |
| 2015-06-30 |
$16.11B |
$22.62B |
70.43% |
| 2015-03-31 |
$15.92B |
$19.51B |
65.10% |
| 2014-12-31 |
$16.32B |
$20.70B |
62.16% |
| 2014-09-30 |
$17.32B |
$28.65B |
64.36% |
| 2014-06-30 |
$15.55B |
$28.94B |
63.82% |
| 2014-03-31 |
$15.06B |
$26.76B |
68.32% |
| 2013-12-31 |
$13.83B |
$23.31B |
71.01% |
| 2013-09-30 |
$12.88B |
$18.49B |
75.47% |
| 2013-06-30 |
$12.87B |
$19.62B |
81.73% |
| 2013-03-31 |
$10.44B |
$16.50B |
78.55% |
| 2012-12-31 |
$10.85B |
$13.65B |
68.33% |
| 2012-09-30 |
$8.50B |
$13.19B |
46.80% |
| 2012-06-30 |
$8.74B |
$9.82B |
40.29% |
| 2012-03-31 |
$10.11B |
$26.87B |
38.71% |
| 2011-12-31 |
$9.67B |
$22.80B |
37.70% |
| 2011-09-30 |
$11.40B |
$27.25B |
43.67% |
| 2011-06-30 |
$11.61B |
$27.51B |
45.54% |
| 2011-03-31 |
$12.28B |
$25.05B |
51.06% |
| 2010-12-31 |
$13.33B |
$24.57B |
57.77% |
| 2010-09-30 |
$13.60B |
$24.85B |
62.41% |
| 2010-06-30 |
$13.53B |
$21.76B |
66.77% |
| 2010-03-31 |
$13.29B |
$21.14B |
69.33% |
| 2009-12-31 |
$12.27B |
$19.40B |
69.72% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
